Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial

Authors :: J. Townend
J Huober
Judith R. Kroep
Martine Piccart-Gebhart
S. Di Cosimo
Anna Manukyants
Cristina Saura
Florentine Hilbers
David Cameron
Judith M Bliss
G. Werutsky
M.A. Colleoni
A.Moreno Aspitia
V Van Dooren
P. Nuciforo
E. de Azumbaja
A. Ferro
R. D. Gelber
V. Moebus
Source :: European Journal of Cancer. 138:S15-S16
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Lapatinib
Survival outcome
Clinical trial
Trastuzumab
Internal medicine
HER2 Positive Breast Cancer
Medicine
Open label
business
medicine.drug

Tools